TORO: 96 Week Virological and Immimological Response and Safety Evaluation of Enfuvirtide with an Optimized Background Regimen

摘要

The TORO studies up to week 48 have demonstrated the safety and efficacy of enfuvirtide (ENF) plus an optimized background (OB) compared to OB alone in pre-treated patients. Patients on OB either meeting protocol defined criteria for virological failure from week 8 or at week 48 were permitted to revise their OB and add ENF.